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a b s t r a c t
Papillary tumor of the pineal region (PTPR) was introduced to the WHO classiﬁcation in 2007.
This rare tumor of little known natural history and unpredictable behavior was described in
fewer than 100 cases. Its optimal treatment is not established yet. We report another two
cases of PTPR in whom tumors were totally removed via supracerebellar infratentorial
approach and both were treated with radiotherapy. In a 37-year-old man the operation was
delayed 6 years after the ﬁrst tumor diagnosis and subsequent shunt placement. He has no
complaints 10 years after the onset of the disease. A 45-year-old woman has no complaints
24 months after surgery. Our experience and the data from literature indicate that a total
tumor removal is the major prognostic factor.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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ScienceDirect
journal homepage: http://www.elsevier.com/locate/pjnns1. Introduction
Pineal region tumors of atypical papillary histological appear-
ance were sporadically described already years ago [1,2].
Clinical data were scarce as the surgical treatment of pineal
tumors was not commonly performed then. In 2003 Jouvet
et al. described papillary tumors of the pineal region (PTPR). On
the basis of 6 histologically examined cases, they came to
conclusion that it was a distinct type of the pineal tumor [3]. Its
characteristic histopathological picture was described. Some
years later, in 2007, the tumor was included into the new
revision of the WHO classiﬁcation of CNS tumors [4]. The* Corresponding author at: Klinika Neurochirurgii, Wojskowy Instytut
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0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Ubiological behavior of PTPR is variable and may correspond to
the WHO grades II or III [4]. This rare tumor has been described
in fewer than 100 cases [5,6]. The optimal treatment options
have not been established yet [4,7–9]. The majority of cases
described till now were conﬁrmed histologically, but their
treatment differed. Surgery (biopsy, attempt at gross total
removal, treatment of hydrocephalus) remains the main option,
but still seems insufﬁcient in particular cases. Radiotherapy
and chemotherapy as adjuvant treatment options are com-
monly used, but their value needs to be evaluated. This is
the reason that we report two additional cases of PTPR because
only the multicenter study and growing experience may in
future give better indications for optimal therapy. Medyczny, ul. Szaserów 128, 04-141 Warszawa, Poland.
rban & Partner Sp. z o.o. All rights reserved.
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Among 65 pineal region tumors treated surgically in our
institution in years 1998–2013, histological examinations
revealed 2 cases of PTPR. Both tumors were totally removed
macroscopically via supracerebellar infratentorial approach.
Post-operative materials were submitted to pathology, where
formalin-ﬁxed parafﬁn embedded tissue blocks were pre-
pared. Initial haematoxilin and eosin staining of tissue slides
was followed by additional immunohistochemical and PAS
stainings. The antibodies used in tumor diagnosis were:
cytokeratin (clone AE1/AE3, dilution 1:50), EMA (clone E29,
1:100), CEA (clone Il-7, 1:50), GFAP (clone 6F2, 1:100), NF (clone
2F11, 1:100), NSE (clone BBS/NC/VI-H14, 1:100), synaptophysin
(clone DAK-SYNAP, 1:50) and Ki-67 (clone MIB-1, 1:100), all
manufactured by DAKO, Denmark. Postoperatively both
patients underwent 3D conformal radiotherapy to tumor beds
with margins, with photon energy 6 MeV. Each one received
dosis of 5400 cGy in 30 equal fractions during about 6 weeks.
Case 1. KK, male, 37 years, admitted because of a headache,
hypoacusis, tinnitus and visual worsening lasting 10 days.
6 years earlier the diagnosis of a pineal tumor with
hydrocephalus was established in another hospital and the
patient underwent shunt placement. On admission, only
hypoacusis was found. Routine blood tests, serum alpha-
fetoprotein (AFP) and beta-human chorionic gonadotropin
(bCG) levels were normal. MRI with signiﬁcant contrast
enhancement revealed a pineal tumor of heterogenous
morphology with cystic components, 49 mm  31 mm 
27 mm in size. The tumor penetrated the third ventricle,
pressed cerebral peduncles and cerebellar vermis (Fig. 1). As
the shunt worked correctly there was no hydrocephalus.
At the time of surgery, the tumor was grayish, soft,
contained cysts with yellow ﬂuid, did not bleed. The borders
were clear except for the right thalamus, which seemed
inﬁltrated. Postoperatively the patient had diplopia, nauseaFig. 1 – Case no. 1. MRI of papillary tumor of the pineal region, s
examination. Left – 4 years after the operation.and improvement of hearing. Discharged home on the 9th
postoperative day with diplopia. Later he proceeded to
adjuvant radiotherapy. 47 months after the operation and
more than 9 years from the onset of the disease he feels well, is
professionally active, with no complaints and with no residual
tumor in MRI scans (Fig. 1).
Histologically the tumor was composed of epithelioid cells
forming papillary structures and solid areas (Fig. 2A). Among
tumor cells with little atypia, foci of highly atypical cells were
observed. Despite conspiciuous cell morphology, increased
mitotic activity was absent in such areas. No tumor necrosis,
nor vascular proliferations were found (Fig. 2B). In immuno-
histochemical stainings neoplastic cells were positive to
cytokeratin (Fig. 2C). The same cells were found to be EMA-,
CEA-, GFAP-, NF- and synaptophysin-negative. Low Ki-67
labeling index of tumor cells reﬂected low proliferative activity
of the neoplasm (Fig. 2D). In cytoplasm of neoplastic cells PAS-
positive granules were found (Fig. 2E). Based on histology and
immunophenotype of neoplastic cells, diagnosis of PTPR was
made (Fig. 2).
Case 2. BA, female, 45 years, with a 2-month history of
imbalance, all limbs painful and weak, urinary incontinence
for 2 years, arterial hypertension for 3 years. On admission
neurological examinations showed imbalance, left side
hemiparesis, hypoestesia on the right side of the trunk,
bilateral ataxia. Cranial nerves were normal. Routine blood
tests, serum AFP and bhCG levels were normal. MRI scan
revealed a heterogenous, strongly contrast enhanced mass in
the pineal region, the third ventricle, cerebral aqueduct and
quadrigeminal cistern with small cystic components. The
tumor was 22 mm  15 mm  14 mm in size and caused
obstructive hydrocephalus with periventricular edema
(Fig. 3). At operation it was grayish, soft, inﬁltrating right
thalamus. Postoperatively she had ocular discoordination
with the Parinaud syndrome, psychomotor slowing and
pneumocephalus. She was discharged home on the 21st
postoperative day. Radiotherapy was used. 17 months later noagittal section, contrast enhancement. Right – preoperative
Fig. 2 – Case no. 1. Tumor histology. A – Papillary areas of tumor (H&E staining, 200T). B – Area of tumor cells with greater
atypia, but without increased mitotic activity (H&E, 200T). C – Expression of cytokeratin by neoplastic cells in
immunohistochemistry (anti-CK, 200T). D – Minimal nuclear staining of tumor cells with anti-Ki-67 antibody (anti-Ki67,
200T). E – PAS-positive cytoplasmic granules in tumor cells – such finding might correspond to ultrastructural features of
partial secretory differentiation of tumor cells (PAS staining, 400T).
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 3 5 6 – 3 6 2358residual tumor was found in MRI exam (Fig. 3), hydrocephalus
disappeared and the patient felt well though imbalance and
slight diplopia persisted.
Histologically the tumor was composed of monomorphous
population of medium-sized epithelioid cells with little atypia,
forming papillary structures with vascular stalk. Solid areas of
tumor cells were also present, accompanied with perivascular
pseudorosettes (Fig. 4A). No foci of necrosis, conspicuous
mitotic activity, nor vascular proliferation were present. The
tumor cells were immunopositive to cytokeratin (Fig. 4B).
Immunopositivity to neuron speciﬁc enolase (NSE) was
detected (Fig. 4C), but the tumor cells were immunonegativeto other neuronal markers, such as synaptophysin or
neuroﬁlament (NF) (Fig. 4D), as well as to glial ﬁbrillary acidic
protein (GFAP). Similarly to Case No 1 few tumor cells
expressed Ki-67 antigen (Fig. 4E). The neoplastic cells were
PAS-negative. The histological diagnosis of WHO grade II PTPR
was established (Fig. 4).
3. Discussion
PTPR is a pineal tumor encountered both in adults and in
children [10–13]. The average age of patients is 32–34 years
Fig. 3 – Case no. 2. MRI of papillary tumor of the pineal region, sagittal section, contrast enhancement. Right – preoperative
examination. Left – 4 months after the operation.
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tumors. They mainly consist of a headache due to obstruc-
tive hydrocephalus, visual impairment, gait disturbances.
Tumors at the time of diagnosis are quite big, being 5–50 mm
in diameter (average 29 mm) and nearly in half of the
patients they cause hydrocephalus [14]. In the majority of
MR imaging reports of PTPR, the tumor looks like a
heterogeneously enhanced pineal region mildly lobulated
mass with cystic compartments [3,15–17]. The intrinsic
hyperintensity on non-contrast T1-weighed sequences in
the absence of fat, hemorrhage, melanin or calciﬁcations is
considered to be a characteristic MRI appearance of this
tumor [15]. This, however, is not true in all cases [18,19].
Histological diagnosis of PTPR is difﬁcult, as the tumor may
resemble other pineal region tumors with papillary features.
PTPR may sometimes be distinguished from papillary
ependymoma, papillary meningioma, choroid plexus papil-
loma or carcinoma and even metastatic papillary carcinoma
on the basis of thorough immunohistochemical staining
only [3,7,20]. Before the deﬁnition of PTPR was given these
kinds of tumors had been sometimes diagnosed erroneously
according to old experiences, but nowadays after reexami-
nation and additional stainings done they seem PTPR [21,22].
It is postulated that this tumor derives from specialized
ependymocytes of the subcomissural organ in the third
ventricle [3].
Cases reported in the relevant literature, rarely in larger
series, show that the natural course of the disease is
unpredictable. Therefore establishing optimal treatment
indications seems difﬁcult. PTPR is considered to be the
WHO II or III grade, however the exact histological grading
criteria have not been explained precisely yet [4,7,14,23].
Tumor might exhibit slow progression and long clinical
course, as was in the case no. 1 reported here [24–26]. However
local recurrences are frequent [5,11,14,27], CSF spinal dissemi-
nation or meningeal spread may occur [3,5,8,14,28–31].Treatment modalities differ. The most common choice is
an attempt at gross total surgical tumor removal and
postoperative adjuvant radiotherapy. In the series of 72 cases
collected from the literature by Poulgrain et al. [14], surgical
tumor removal was performed in 87% of the patients. In 11%
only the biopsy was done. In many cases the coexisting
hydrocephalus had to be treated. Radiation with different
methods and extent was used in 61% of cases.
In a quite extensive retrospective multicenter study of
44 cases of PTPR, the statistical analysis showed that the
extent of the surgery was the only clinical factor associated
with a better overall survival [8]. Radiotherapy did not
inﬂuence the overall survival nor progression-free survival.
This analysis proved chemotherapy also ineffective. This
study conﬁrmed a high risk for PTPR recurrence (58% at
5 years, 70% at 6 years).
On the other hand, tumor regression after radiotherapy
[10,32] or even tumor disappearance [33] was observed. Whole
brain irradiation, local radiotherapy, gamma knife surgery,
stereotactic linac radiosurgery were all used with different
protocols [32,34,35]. A good local control of tumor was
achieved in a few cases treated with interstitial brachytherapy
with 125Iodine seeds [36].
When surgery and radiotherapy were ineffective, long
lasting tumor regression could be sometimes obtained after
chemotherapy with temozolomide [37]. Temozolomide with
etoposide, etoposide with carboplatin, ACNU were all used in
PTPR treatment with various results [30,38,39]. A successful
long-term response to bevacizumab, an antiangiogenic anti-
body against vascular endothelial growth factor, in a refractory
recurrent multifocal PTPR was recently described [6].
No optimal therapy of PTPR is established yet, so even in
the same institution patients are treated differently according
to the individual neurosurgical and oncological evaluation of a
case, its histological pattern and other factors which may be
difﬁcult to identify [31,40,41].
Fig. 4 – Case no. 2. Tumor histology. A – Neoplastic papillary structures (H&E, 200T). B – Expression of cytokeratin by tumor
cells (anti-CK, 200T). C – Expression of NSE by tumor cells (anti-NSE, 200T). D – NF-negative tumor cells infiltrating adjacent
NF-positive non-neoplastic tissues of pineal region (top left) (anti-NF, 400T). E – Low Ki-67 labeling index of tumor cells
reflecting low proliferative activity of the neoplasm (anti-Ki-67, 200T).
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PTPR is a very rare tumor of the pineal region with
unpredictable course and proclivity for local recurrence and
seeding. Sometimes, however, the course of the disease is
long. The only positive prognostic clinical factor improving an
overall survival rate is gross total resection of the tumor mass.
Other methods do not offer the permanent cure. For that
reason, and because of the heterogenous tumor nature, all
kinds of biopsies (stereotactic or endoscopic) should be
avoided and the goal of the surgery should be a complete
tumor resection. Further experience with a larger number of
cases is needed to establish optimal treatment guidelines.
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